ERBB2 and invasive breast carcinoma: The Oncotype DX Recurrence Score (ODX-RS) has been considered a crucial element in the management pathway of oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, lymph node-negative/micrometastasis/N1 (one to three nodes positive) early invasive breast cancer and aids the physician to predict which patients would attain minimal or no benefit from adjuvant chemotherapy and would be safely spared from its adverse effects, without compromising outcomes [1].